ライフサイエンスコーパス: drug-metabolizing enzyme

1 cytochrome P450 3A4, the major human hepatic drug-metabolizing enzyme.

2 tion of cytochrome P450 3A4, the major human drug-metabolizing enzyme.

3 e the drug metabolism by administration of a drug-metabolizing enzyme.

4 cytochrome P4503A4 (CYP3A4), the major human drug-metabolizing enzyme.

5 Human SULT1A1 is an important phase II drug-metabolizing enzyme.

6 tein cytochrome P450 3A4 (CYP3A4) is a major drug-metabolizing enzyme.

7 -2 (NAT2) gene, which expresses an important drug-metabolizing enzyme.

8 ls of hepatic multicytochrome P450-dependent drug metabolizing enzymes.

9 g efflux transporters and cytochrome P450 3A drug-metabolizing enzymes.

10 lating the hepatic genes that encode various drug-metabolizing enzymes.

11 gnized as one of the most important phase II drug-metabolizing enzymes.

12 the activation of cytochrome P450-containing drug-metabolizing enzymes.

13 450 cytochromes that form the major class of drug-metabolizing enzymes.

14 r promotion, and induction of genes encoding drug-metabolizing enzymes.

15 rch developments in the understanding of the drug-metabolizing enzymes.

16 receptors are transcriptional regulators of drug metabolizing enzymes and drug export pumps, but onl

17 d on the simultaneous downregulation of many drug metabolizing enzymes and transporter genes.

18 e discuss the importance of polymorphisms in drug metabolizing enzymes and transporters in anticancer

19 MET, and KRAS mutations and polymorphisms in drug metabolizing enzymes and transporters were evaluate

20 obiotics and regulates expression of several drug metabolizing enzymes and transporters.

21 Cytochrome P450 (CYP) 3A4 is a major human drug-metabolizing enzyme and displays pharmacologically

22 ly considered to be the most important human drug-metabolizing enzyme and is known to catalyze the ox

23 tiretroviral therapy (HAART), antiretroviral drug-metabolizing enzyme and transporter gene polymorphi

24 ter including CCR2 190G>A as well as all the drug-metabolizing enzyme and transporter genotypes.

25 in Mdr1a(-/-) rats, the expression levels of drug-metabolizing enzyme and transporter-related genes w

26 tion by regulating the expression of phase I drug-metabolizing enzymes and ATP-binding cassette (ABC)

27 cific isoforms of cytochrome P450, the major drug-metabolizing enzymes and constituting approximately

28 cogenetics explores how genetic variation in drug-metabolizing enzymes and drug targets modifies resp

29 A variants in additional genes that code for drug-metabolizing enzymes and drug transport proteins wa

30 y regulates the expression of genes encoding drug-metabolizing enzymes and drug transporters to essen

31 Elevated levels of drug-metabolizing enzymes and efflux transporters, resul

32 ocyte hypertrophy, and induced expression of drug-metabolizing enzymes and other liver-specific genes

33 ional factors, such as germline mutations in drug-metabolizing enzymes and other pharmacogenomic alte

34 The transcriptional regulation of drug-metabolizing enzymes and transporters (here collect

35 NR1I3) regulates the expression of multiple drug-metabolizing enzymes and transporters in liver.

36 proteins was undertaken using the Affymetrix drug-metabolizing enzymes and transporters panel.

37 modulating the expression of genes encoding drug-metabolizing enzymes and transporters.

38 and a paramount transcriptional regulator of drug-metabolizing enzymes and transporters.

39 endobiotics by regulating the expression of drug-metabolizing enzymes and transporters.

40 ng triggers the trans-activation of critical drug-metabolizing enzymes and transporters.

41 nvolved in the transcriptional regulation of drug-metabolizing enzymes and transporters.

42 tochrome P450 (CYP3A4, the major human liver drug-metabolizing enzyme) and its role in the degradatio

43 showed that CYP3A4, the dominant human liver drug-metabolizing enzyme, and its rat liver orthologs un

44 idant and antimutagen and to induce phase II drug-metabolizing enzymes (anti-initiation activity); it

45 e activity in animal models by modulation of drug-metabolizing enzymes are sulforaphane, an aliphatic

46 ridine diphosphate glucuronosyltransferases) drug-metabolizing enzymes are the autoantigens of syndro

47 rinduction of multicytochrome P450-dependent drug metabolizing enzymes as well as an overexpression o

48 de (1) increased appreciation of the role of drug-metabolizing enzymes, both in determining the predi

49 n of cytochrome P450 3A4 (CYP3A4), the major drug metabolizing enzyme, by dietary compounds has recen

50 An oral cocktail of probe drugs for major drug-metabolizing enzymes (caffeine, tolbutamide, omepra

51 concentration which a given concentration of drug-metabolizing enzyme can effectively prevent from en

52 rug interactions caused by the inhibition of drug-metabolizing enzymes can now be predicted and exami

53 Substrates of a major drug-metabolizing enzyme CYP2D6 display increased elimin

54 The drug-metabolizing enzyme CYP3A4 is often implicated in t

55 The drug metabolizing enzyme cytochrome P450 3A4 (CYP3A4) is

56 and binding and allostery in the major human drug-metabolizing enzyme cytochrome P450 3A4 (CYP3A4) we

57 The activities of two other major drug-metabolizing enzymes (cytochrome P450 3A4 and 2D6 [

58 of genetic variation, including variation at drug metabolizing enzyme (DME) loci and drug targets, in

59 C), particularly involving genes that encode drug metabolizing enzymes (DMEs).

60 Differential expression of various drug-metabolizing enzymes (DMEs) in the human liver may

61 merging examples of genetic polymorphisms of drug-metabolizing enzymes, DNA repair genes and drug tar

62 tocol for detecting key polymorphisms in the drug-metabolizing enzyme gene CYP2D6 and a number of lin

63 nd urea synthesis, as well as phase I and II drug-metabolizing enzyme gene expression and activity of

64 A principal advance in the production of drug-metabolizing enzymes has been the development of ca

65 Drug metabolizing enzymes have been studied for decades,

66 P-glycoprotein (P-gp) and the drug metabolizing enzymes have major pharmacokinetic eff

67 The drug-metabolizing enzyme human carboxylesterase 1 (hCE1)

68 trans-Stilbene oxide (TSO) induces drug metabolizing enzymes in rat and mouse liver.

69 The role of cytochrome P450 drug metabolizing enzymes in the efficacy of tamoxifen t

70 macological relevance, and AOX3 is the major drug-metabolizing enzyme in rodents.

71 the CYP3A enzymes, the most abundant phase I drug-metabolizing enzymes in human liver and intestine,

72 l activation of many genes encoding phase II drug-metabolizing enzymes in response to oxidative stres

73 Cytochromes P450 3A4 and 3A5, the dominant drug-metabolizing enzymes in the human liver, share >85%

74 cytochrome P450 3A (CYP3A) members are major drug-metabolizing enzymes in the liver.

75 athway has been identified as a regulator of drug-metabolizing enzymes in the rodent liver.

76 Genotypes in drug-metabolizing enzymes, including functional polymorp

77 re the most versatile and important class of drug-metabolizing enzymes, involved in the metabolism of

78 Understanding of drug-metabolizing enzymes is key to the science of pharm

79 CYP3A4, the dominant human liver drug-metabolizing enzyme, is degraded via a ubiquitin (U

80 Cytochrome P450 2D6 (CYP2D6), a major drug-metabolizing enzyme, is responsible for metabolism

81 Cytochrome P4503A4 (CYP3A4), a major human drug-metabolizing enzyme, is responsible for the oxidati

82 Human NAT2 is characteristic of drug-metabolizing enzymes: it is found in liver and inte

83 Thus, in addition to the phase I drug-metabolizing enzymes known to be decreased during t

84 the context of the earlier hypothesis that 'drug-metabolizing' enzymes might modulate the processes

85 al to significantly modulate the activity of drug-metabolizing enzymes (notably cytochrome p450 isozy

86 Cytochrome P450 3A4 is a drug-metabolizing enzyme of extraordinarily broad substr

87 es 210-216 of cytochrome P450 3A4, the major drug-metabolizing enzyme of human liver.

88 rane-bound oxidative partners, including the drug-metabolizing enzymes of the cytochrome P450s (P450)

89 n characterizing the effects of variation in drug metabolizing enzymes on pharmacokinetics.

90 The general insights into the effects of a drug-metabolizing enzyme on drug kinetics in human shoul

91 blood levels, and the individual's specific drug-metabolizing enzyme profile may contribute to this

92 man pregnane X receptor (hPXR) to upregulate drug-metabolizing enzymes, resulting in decreased drug e

93 CYP3A, the most important family of drug-metabolizing enzymes, shares many substrates with t

94 The four drug-metabolizing enzymes studied (GST A1-1 and the CYP

95 Genetic variation in drug metabolizing enzymes such as cytochrome P450 2D6 (C

96 of CYP3A4, P-glycoprotein (P-gp), and other drug metabolizing enzymes such as dihydropyrimidine dehy

97 and xenobiotics, leading to the induction of drug-metabolizing enzymes, such as cytochrome P450.

98 Phase II drug-metabolizing enzymes, such as glutathione S-transfe

99 i-tumor immune response, or delivering a pro-drug metabolizing enzyme that will render the tumor sens

100 CYP2C19 is an important human drug-metabolizing enzyme that metabolizes a number of cl

101 re the most versatile and important class of drug-metabolizing enzymes that are induced in mammalian

102 and inflammation affect drug metabolism and drug-metabolizing enzymes, the effect of the acute-phase

103 nzyme are likely to underlie the capacity of drug-metabolizing enzymes to metabolize structurally div

104 tic studies have shown that polymorphisms of drug metabolizing enzymes, transporters and receptors co

105 ociated with polymorphisms in genes encoding drug-metabolizing enzymes, transporters, or drug targets

106 Genetic polymorphisms in drug-metabolizing enzymes, transporters, receptors, and

107 l activation of many genes encoding phase II drug-metabolizing enzymes via the antioxidant response e

108 o the second most important class of phase-1 drug-metabolizing enzymes, was immobilized in its active

109 f genetic polymorphisms in each of the three drug-metabolizing enzymes, which impacts on the therapeu

110 (GSTs) comprise a diverse family of phase II drug metabolizing enzymes whose shared function is the c